Search research articles
Contact Us
Filters
Showing results (41-50 of 278) with videos related to
Page
of 28
Sort By:
The Lancet. Respiratory Medicine
|
February 8, 2018
Idiopathic pulmonary fibrosis: idiopathic no more?
Victor J Thannickal, Athol Wells, Martin Kolb
Respiratory Research
|
January 25, 2002
A new direction in the pathogenesis of idiopathic pulmonary fibrosis?
Jack Gauldie, Martin Kolb, Patricia J Sime
The European Respiratory Journal
|
January 29, 2021
The evolution of the <i>European Respiratory Journal</i>: weathering the publishing pandemic
Martin Kolb, James D Chalmers, Marc Humbert
European Respiratory Review : an Official Journal of the European Respiratory Society
|
February 22, 2023
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
Martin Kolb, Bruno Crestani, Toby M Maher
Arthritis & Rheumatology (Hoboken, N.J.)
|
January 11, 2016
Editorial: Extracellular Matrix: The Common Thread of Disease Progression in Fibrosis?
Martin Kolb, Jack Gauldie, Pierre-Simon Bellaye
The European Respiratory Journal
|
April 1, 2023
Design considerations and implications of findings on progressive pulmonary fibrosis from the prospective Canadian Registry for Pulmonary Fibrosis
Christopher J Ryerson, Nathan Hambly, Martin Kolb
American Journal of Respiratory and Critical Care Medicine
|
February 13, 2016
Mucking around in the Genome: MUC5B in Idiopathic Pulmonary Fibrosis
Martin Kolb, Eric S White, Jack Gauldie
The European Respiratory Journal
|
March 26, 2021
Guideline-directed management of COVID-19: Do's and Don'ts
Martin Kolb, Anh Tuan Dinh-Xuan, Laurent Brochard
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|
July 29, 2005
Transforming growth factor-beta: importance in long-term peritoneal membrane changes
Peter J Margetts, Kook-Hwan Oh, Martin Kolb
Expert Opinion on Emerging Drugs
|
April 8, 2024
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials
Sarah MacIsaac, Dujrath Somboonviboon, Ciaran Scallan, et al.
Page
of 28
Search research articles
Search
Showing results (41-50 of 278) with videos related to
Sort By:
Page
of 28
The Lancet. Respiratory Medicine
|
February 8, 2018
Idiopathic pulmonary fibrosis: idiopathic no more?
Victor J Thannickal, Athol Wells, Martin Kolb
Respiratory Research
|
January 25, 2002
A new direction in the pathogenesis of idiopathic pulmonary fibrosis?
Jack Gauldie, Martin Kolb, Patricia J Sime
The European Respiratory Journal
|
January 29, 2021
The evolution of the <i>European Respiratory Journal</i>: weathering the publishing pandemic
Martin Kolb, James D Chalmers, Marc Humbert
European Respiratory Review : an Official Journal of the European Respiratory Society
|
February 22, 2023
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
Martin Kolb, Bruno Crestani, Toby M Maher
Arthritis & Rheumatology (Hoboken, N.J.)
|
January 11, 2016
Editorial: Extracellular Matrix: The Common Thread of Disease Progression in Fibrosis?
Martin Kolb, Jack Gauldie, Pierre-Simon Bellaye
The European Respiratory Journal
|
April 1, 2023
Design considerations and implications of findings on progressive pulmonary fibrosis from the prospective Canadian Registry for Pulmonary Fibrosis
Christopher J Ryerson, Nathan Hambly, Martin Kolb
American Journal of Respiratory and Critical Care Medicine
|
February 13, 2016
Mucking around in the Genome: MUC5B in Idiopathic Pulmonary Fibrosis
Martin Kolb, Eric S White, Jack Gauldie
The European Respiratory Journal
|
March 26, 2021
Guideline-directed management of COVID-19: Do's and Don'ts
Martin Kolb, Anh Tuan Dinh-Xuan, Laurent Brochard
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|
July 29, 2005
Transforming growth factor-beta: importance in long-term peritoneal membrane changes
Peter J Margetts, Kook-Hwan Oh, Martin Kolb
Expert Opinion on Emerging Drugs
|
April 8, 2024
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials
Sarah MacIsaac, Dujrath Somboonviboon, Ciaran Scallan, et al.
Page
of 28